Immunization with the pneumococcal proteins pneumolysin (Ply), choline binding protein A (CbpA), or pneumococcal surface protein A (PspA) elicits protective responses against invasive pneumococcal disease in animal models. In this study, we used different mouse models to test the efficacy of a variety of multivalent protein-based vaccines that comprised various combinations of full-length or peptide regions of the immunogens Ply, CbpA, or PspA: Ply toxoid with the L460D substitution (referred to herein as L460D); L460D fused with protective peptide epitopes from CbpA (YPT-L460D-NEEK [YN]); L460D fused with the CD2 peptide containing the proline-rich region (PRR) of PspA (CD2-L460D); a combination of L460D and H70 (L460D+H70), a slightly larger PspA-derived peptide containing the PRR and the SM1 region; H70+YN; and other combinations. Each mouse was immunized either intraperitoneally (i.p.) or subcutaneously (s.c.) with three doses (at 2-week intervals) of the various antigen combinations in alum adjuvant and then challenged in mouse models featuring different infection routes with multiple Streptococcus pneumoniae strains. In the i.p. infection sepsis model, H70+YN consistently provided significant protection against three different challenge strains (serotypes 1, 2, and 6A); the CD2+YN and H70+L460D combinations also elicited significant protection. Protection against intravenous (i.v.) sepsis (type 3 and 6A challenge strains) was largely dependent on PspA-elicited immune responses. This vaccine type strain through natural genetic transformation (3, 8). This second scenario may be of greater potential significance, as it enables highly transmissible, virulent, and often antibiotic-resistant clones to escape the PCV. More recently licensed PCVs have increased serotype coverage (10- and 13-valent) (9, 10), but this is at best only a stop-gap measure. The emergence of a high proportion of virulent strains outside the 13-valent vaccine coverage has recently been documented in the high-risk sickle cell disease population (11).
Pneumococcal protein-based vaccine formulations comprising combinations of conserved virulence proteins that function at different stages of pathogenesis offer an attractive alternative to PCVs. Three proteins stand out as the best candidate vaccine antigens, namely, pneumolysin (Ply), pneumococcal surface protein A (PspA), and choline binding protein A (CbpA) (also known as PspC). These proteins elicit some of the highest antibody titers in sera from humans exposed to pneumococci (12–15), and their functions in pathogenesis are well characterized, involving processes in all body compartments (16–22).

Ply is a cholesterol-binding toxin produced by virtually all strains of S. pneumoniae. It was one of the first virulence-related proteins identified in S. pneumoniae, and its cytotoxicity emanates from its capacity to insert into eukaryotic cell membranes and oligomerize to form large transmembrane pores, resulting in cell lysis (17). A number of immunogenic pneumolysoids generated by point mutations in the ply gene have reduced cytotoxicity and provide significant protection against different serotypes of S. pneumoniae at multiple stages of infection in various murine models. One such toxoid, PdB, has a single substitution (W433F) that reduces hemolytic activity by >99% (23), and it is one of the most well-studied antigens. It protects mice from diverse S. pneumoniae strains when used as either a single immunogen or in combination with other proteins, particularly PspA and CbpA (24–28). More recently, a triple mutant toxoid, PlyD1 (comprising T65C, G293C, and C428A mutations), with only 0.001% residual hemolytic activity, was also shown to elicit protection against pneumococcal infection and lung injury (29). A novel Ply toxoid devoid of detectable cytotoxicity contains an L460D substitution, which disrupts a threonine-leucine pair that comprises a CDC. Due to its undetectable cytotoxicity, PlyL460D (referred to as L460D herein) is potentially a more suitable vaccine candidate than PdB.

PspA is one of the best-characterized members of the choline binding protein family. It is found on the surfaces of all pneumococci and has important roles in the pathogenesis of disease (31, 32). During invasive disease, it interferes with complement-dependent host defense and thereby reduces the deposition of complement on the cell surface; concomitantly, it impairs complement receptor-mediated clearance. PspA also blocks killing by host cationic bactericidal peptides (33) and interferes with phagocytosis by a complement-independent mechanism (34). The PspA protein consists of three main regions: the N-terminal alpha-helical domain, a proline-rich region (PRR), and a choline binding domain. Previous studies have focused on the N-terminal alpha-helical domain of PspA, which elicits protection against invasive disease (28, 35–37). However, the alpha-helical domain of PspA is variable in terms of its amino acid sequence and antigenic epitopes (38–41). Attention has recently shifted to the PRR, as this region is much more conserved and contains epitopes on the pneumococcal surface that are antibody accessible (42). The PRR has also been shown to elicit broader cross-reactive antibodies and cross-protection against pneumococcal infection (42, 43).

Another well-characterized pneumococcal choline binding protein is CbpA, which participates in pneumococcal adherence to host cells and helps pneumococci evade complement attack and opsonophagocytosis. CbpA plays important roles in many stages of disease and elicits protection against pneumococcal infection in different animal models (20, 26, 27, 44–46). The N-terminal domain of CbpA binds to the secretory component of secretory immunoglobulin A (sIgA), C3, factor H, and the laminin receptor (47–52). This domain consists of two nearly identical repeat regions that each assemble into antiparallel helices (not-coiled coils), and the turns between the helices show extremely high conservation across most pneumococcal strains (49, 53). An RRNYPT sequence in the first turn binds to the epithelial polymeric immunoglobulin receptor (pIgR), and the EPRNEEK sequence in the second turn binds to the laminin receptor on the blood-brain barrier endothelium (52). Recently, a recombinant fusion protein consisting of these two turns fused to either terminus of L460D has been shown to elicit broad protection against multiple stages of pneumococcal infection (54).

The aim of the present study was to develop a multivalent and broadly efficacious pneumococcal protein vaccine via a thorough examination of the protective immunogenicity of the proteins L460D, CbpA, and PspA. Vaccine candidates consisted of either full-length or peptide derivatives of these proteins, recombinant fusion proteins comprising immunogenic regions from these proteins fused to the full length or portions of one of the other proteins, or these in various combinations. The resultant multivalent protein candidates were tested for protective efficacy in different animal models against a wide range of pneumococcal challenge strains to establish the optimal formulation of a multivalent vaccine.

### Materials and Methods

#### Bacterial strains and growth conditions

The bacterial strains used in this study are listed in Table 1. S. pneumoniae serotype 4 bioluminescent strain TIGRAX was grown in chemically defined medium (C+Y) without aeration at 37°C in 5% CO2 to an optical density at 620 nm (OD620) of 0.4 to 0.5 (54). S. pneumoniae strains D39, 1861, and P9 were grown in serum broth to an OD600 of 0.18, as previously described (55). S. pneumoniae strains DBL6A, A66.1, and EF3030 were grown in Todd-Hewitt broth to an OD600 of 0.4, as previously described (42).

#### Construction and production of recombinant proteins

The features of the recombinant proteins and expression constructs used in this study are presented in Table 2. The PCR primers used for subcloning are listed in Table 3. All expression constructs were sequenced at the St. Jude Children’s Research Hospital (SJCRH) Hartwell Center. All proteins were purified by the SJCRH Protein Production Facility and stored in 10 mM histidine buffer (pH 6.0) with 15% trehalose.

#### Pneumolysoid

The ply gene was first PCR amplified from strain D39 and then cloned into vector pQE30. The L460D substitution was then introduced by overlapping PCR, as previously described (56). The resulting plasmid, pQE30-L460D, was used as the template to obtain the L460D gene by using primers PLYNDE and PLYSAC, and the L460D gene was subse-

---

**Table 1. S. pneumoniae challenge strains used in this study**

| Strain | Capsular type | Origin |
|--------|---------------|--------|
| D39    | 2             | 26     |
| 1861   | 1             | 55     |
| P9     | 6A            | This study |
| TIGR4  | 4             | 54     |
| EF3030 | 19F           | C. Svanborg |
| A66.1  | 3             | This study |
| DBL6A  | 6B            | This study |

---

Downloaded from http://cvi.asm.org on July 21, 2018 by guest
TABLE 2 Features of recombinant proteins and expression constructs

| Construct | Protein(s) expressed (aa) | Source strain(s) | Template for cloning | 5’ primer | 3’ primer |
|-----------|---------------------------|------------------|----------------------|-----------|----------|
| L460D     | Pneumolysoid              | D39              | pQE30-L460D          | PLYNDE    | PLYSAC   |
| CD2       | PspA proline-rich region  | AC094            | gDNA                 | P15-up-LIC| P15-down-LIC|
| H70       | PspA proline-rich region and SM1 | Rx1 | pIDTSMART-H70a | H70NDE    | H70SAC   |
| pUAB055   | PspA (1–302)              | Rx1              | gDNA                 | pspA1-F   | pspA6-R  |
| rCbpA     | CbpA (175–443)            | TIGR4            | gDNA                 | A175NDE   | A443SAC  |
| YPT-L460D-NEEK (YN) | Pneumolysoid and CbpA peptides | TIGR4 and D39 | pET28-L460D | YPTNDE    | NEEKSAC  |
| CD2-L460D | PspA peptide and pneumolysoid | AC094 and D39 | pCD2, pET28-L460D | CD2NDE    | PLYSAC   |

a Initial construct made by Integrated DNA Technologies.

TABLE 3 PCR primers used in this study

| Primer     | Sequence (5’-3’)          |
|------------|---------------------------|
| PLYNDE     | CGCGGGCGCATATGGCAGAATAGCTGAC |
| PLYSAC     | GGGGCGGAGCTTTATGAATTTCCATTTT |
| YPTNDE     | CGCGGGCGCATATGGCAGAATAGCTGAC |
| NEEKSAC    | CCAATTTTACAAAAACGCGTTGGAAAGT |
| A175NDE    | GGGCGGCGATATGGCAGAATAGCTGAC |
| A443SAC    | GGGGCGGAGCTTTATGAATTTCCATTTTA |
| CD2NDE     | GGGCGGCGATATGGCAGAATAGCTGAC |
| CD2F2      | GGGGGATATGGCAGAATAGCTGAC   |
| CD2R1      | GGGGGATATGGCAGAATAGCTGAC   |
| H70NDE     | GGGGGATATGGCAGAATAGCTGAC   |
| H70SAC     | GGGGGATATGGCAGAATAGCTGAC   |
| p15-up-LIC | GACGACGACAGATGGCAGAATAGCTGAC |
| p15-down-LIC | GACGACGACAGATGGCAGAATAGCTGAC |
| pspA1-F    | GGGGATATGGCAGAATAGCTGAC   |
| pspA6-R    | GGGGATATGGCAGAATAGCTGAC   |
| EKLIC-BglII | GACGACGACAGATGGCAGAATAGCTGAC |
| EKLIC_SM1-ProR | GACGACGACAGATGGCAGAATAGCTGAC |

October 2015 Volume 22 Number 10 cvi.asm.org

This recombinant plasmid was then transformed into Escherichia coli strain BL21(DE3) cells for protein production.

CbpA derivatives and fusion proteins. CbpA derivatives YPT and NEEK from TIGR4 were constructed as previously described (54). Briefly, YPT-L460D-NEEK (YN) and L460D-NEEK were both constructed by incorporating the constrained CbpA sequences of YPT and NEEK into the primers used to amplify L460D. The construction of the YLN fusion protein was previously described (54). Each fragment was cloned into the vector pET28a (Novagen), and the desired constructs were verified by DNA sequencing.

PspA derivatives and fusion proteins. The construction of pUAB055, carrying genes encoding a truncated version of PspA containing the N-terminal region (amino acids [aa]1 to 302), was described previously (39). Briefly, a pUAB055 fragment was amplified by PCR from S. pneumoniae strain Rx1 using primers pspA1-F and pspA6-R and was then cloned into vector pCR1 (Invitrogen) to form plasmid pCR1-pUAB055. This recombinant plasmid was then digested with NcoI and XhoI to obtain the 918-bp pUAB055 fragment. This recombinant plasmid was then cloned into the NcoI/XhoI sites of vector pET20b. The resulting plasmid was then transformed into the E. coli strain RosettaBlue (DE3) pLyS for protein production.

The construction of peptide CD2 was previously described (42). It contains the proline-rich region (PRR) of the PspA from S. pneumoniae strain AC094. Briefly, the PspA (315 bp) was PCR amplified using the primers pspA1-F and pspA6-R, and the resulting PCR fragment was then cloned into vector pET46-Ek/LIC and verified by DNA sequence to confirm its insertion of the expected 393-bp fragment. This recombinant plasmid was then used as the template to obtain an H70 fragment using primers H70NDE and H70SAC, and it was subsequently cloned into vector pET28a (Novagen). The resulting recombinant pET28a-H70 was then transformed into BL21(DE3) cells for protein production.

Intraperitoneal sepsis model. All animal experiments were carried out in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (57) and the South Australian Animal Welfare Act 1985 (58) and were approved by the animal ethics committee of the University of Adelaide, South Australia, Australia. Outbred 4- to 6-week-old female CD1 (Swiss) mice were used in all intraperitoneal (i.p.) sepsis experiments. Each mouse was immunized i.p. three times with 100 µl of 5% saline containing 10 µg of each protein and 200 µg of alum adjuvant (Alhydrogel; InvivoGen) at 14-day intervals. Serum samples were collected from the mice by submandibular bleeding 1 week after the third immunization. A week later, the mice were challenged i.p. with strains D39 (2.5 × 10⁵ CFU, serotype 2), P9 (5 × 10⁵ CFU, serotype 6A), and 1861 (5 × 10⁸ CFU, serotype 1). The infected mice were observed for up to 21 days to determine the number of days until they were moribund.

Meningitis/sepsis model. The experiments were approved by the St. Jude Institutional Animal Care and Use Committee and were carried out essentially as previously described (54). Briefly, 6- to 7-week-old female mice were injected with 0.5% saline containing 10³ CFU, serotype 1) and 10⁴ CFU, serotype 2), P9 (5 × 10⁵ CFU, serotype 6A), and 1861 (5 × 10⁸ CFU, serotype 1). The infected mice were observed for up to 21 days to determine the number of days until they were moribund.

Use of Animals for Scientific Purposes (57) and the South Australian Animal Welfare Act 1985 (58) and were approved by the animal ethics committee of the University of Adelaide, South Australia, Australia. Outbred 4- to 6-week-old female CD1 (Swiss) mice were used in all intraperitoneal (i.p.) sepsis experiments. Each mouse was immunized i.p. three times with 100 µl of 5% saline containing 10 µg of each protein and 200 µg of alum adjuvant (Alhydrogel; InvivoGen) at 14-day intervals. Serum samples were collected from the mice by submandibular bleeding 1 week after the third immunization. A week later, the mice were challenged i.p. with strains D39 (2.5 × 10⁵ CFU, serotype 2), P9 (5 × 10⁵ CFU, serotype 6A), and 1861 (5 × 10⁸ CFU, serotype 1). The infected mice were observed for up to 21 days to determine the number of days until they were moribund.

Meningitis/sepsis model. The experiments were approved by the St. Jude Institutional Animal Care and Use Committee and were carried out essentially as previously described (54). Briefly, 6- to 7-week-old female mice were injected with 0.5% saline containing 10³ CFU, serotype 1) and 10⁴ CFU, serotype 2), P9 (5 × 10⁵ CFU, serotype 6A), and 1861 (5 × 10⁸ CFU, serotype 1). The infected mice were observed for up to 21 days to determine the number of days until they were moribund.

Trivalent Pneumococcal Protein Vaccine
BALB/c mice were immunized i.p. with 10 μg of protein containing 130 μg of alum (Brenntag), and subsequent boosts were given at weeks 2 and 4. Serum samples were collected from the mice at week 5 for functional antibody analysis. The mice were challenged intratracheally (i.t.) with 1 \times 10^7 CFU of TIGR4X (serotype 4) at week 7, and survival was monitored for 14 days. Meningitis was observed by physical signs and confirmed through Xenogen imaging and plating of cerebrospinal fluid samples. Nasal washes of the survivors were collected and plated on day 14 post-challenge.

Intravenous sepsis model and i.t. focal pneumonia models. These experiments were approved by the University of Alabama at Birmingham (UAB) Animal Care Committee. This intravenous (i.v.) sepsis model was carried out as previously described (42). Briefly, CBA/N mice were immunized subcutaneously (s.c.) three times at 2-week intervals with 100 μl containing 5 μg of protein adjuvanted with alum. Three weeks after the last immunization, blood samples were taken from the mice for enzyme-linked immunosorbent assay (ELISA). The following day, the mice were infected i.v. with 4 \times 10^3 CFU of strain A66.1 (serotype 3) or DBL6A (serotype 6B) diluted from a frozen infectious stock in lactated Ringer’s solution containing 7.8% glycerol. The infected mice were observed for up to 21 days to determine the number of days until they were moribund.

In the i.t. focal pneumonia model, CBA/N mice were immunized as described above, except for the challenge, for which mice were first anesthetized lightly with isoflurane and then challenged i.t. with 5 \times 10^6 CFU of S. pneumoniae strain EF3030 (serotype 19F), as described previously (28). On day 5 postinfection, the mice were euthanized, and blood and lungs were harvested and plated for CFU recovery.

**Measurement of antibody responses.** Antigen-specific antibody responses were determined by ELISA using serum samples collected from immunized mice, as previously described (42, 59).

**Hemolysis and anti-hemolytic activity assays.** The hemolytic activity of pneumolysin and the capacity of murine serum to neutralize the hemolytic activity of wild-type Ply were assayed, as previously described (60).

**Statistical analysis.** Statistical analysis was carried out using GraphPad Prism 6. The Mann-Whitney U test (two-tailed) was used for all statistical comparisons carried out in this study (median survival, CFU recovery, and antibody levels). *P* values of <0.05 were considered statistically significant.

**RESULTS**

**Construction of multivalent protein vaccine candidates.** L460D, CbpA, PspA, and their various derivatives (Fig. 1) were tested to determine the optimum formulation of a multivalent vaccine. The immunogens were formulated as mixtures of one, two, or three...
proteins/peptides. Formulations that included L460D consisted of full-length L460D alone or as a fusion construct with the PspA peptide CD2 (CD2-L460D) or with either one or two constrained CbpA peptides (L460D-NEEK or YPT-L460D-NEEK [YN] [54]). Derivatives of PspA were also mixed as separate proteins with L460D or YLN.

All of the constructs were purified at the St. Jude Protein Production Facility and then tested for purity, size, concentration, and contamination with endotoxin. Analysis by SDS-PAGE (Fig. 2A) showed that all proteins migrated according to their respective molecular sizes, except for CD2 and H70, which migrated more slowly than predicted: CD2 is 13 kDa but migrated at 25 kDa, and H70 is 15 kDa but migrated at 33 kDa. This anomalous electrophoretic mobility is likely due to their high proline content. The complete absence of hemolytic activity of purified L460D and its fusion derivatives was confirmed by hemolysis assay (Fig. 2B).

**Immunogenicity of the multivalent protein vaccine candidates.** Groups of 12 to 15 mice (BALB/c or CD1) were immunized intraperitoneally (i.p.) or subcutaneously (s.c.) with each of the various antigens, singly or in combination, using alum adjuvant. Mice were injected three times at 2-week intervals (see Materials and Methods). A serum sample was then collected from each mouse 1 week after the final immunization for analysis of antibody responses. Antigen-specific IgG responses were measured by ELISA, using L460D, recombinant CbpA (rCbpA), or H70 as a coating antigen (Fig. 3). All vaccine formulations elicited strong antibody responses to L460D, with geometric mean (GM) anti-L460D IgG titers of 4,000 for all groups, compared to 200 for the alum placebo group (Fig. 3A).

Pneumolysin antibodies are expected to neutralize the wild-type toxin. Accordingly, the capacity of sera from mice immunized with the various L460D-containing formulations to neutralize the hemolytic activity of wild-type pneumolysin was also assessed (Fig. 3B). All vaccine formulations elicited significant toxin-neutralizing responses (GM antihemolytic titers, ~300, compared with approximately 20 for the alum placebo group). Analysis of CbpA-specific antibody levels also showed strong responses (GM ELISA titers, >3,000) for all groups immunized with antigens containing...
YLN relative to the responses for the alum placebo group and antigen formulations lacking the CbpA-derived peptide epitopes (GM ELISA titers, <200) (Fig. 3C). However, in CD1 mice, both the H70-plus-YLN combination (H70+YLN) and CD2+YLN elicited significantly higher anti-CbpA levels than YLN alone (P < 0.0001 for both groups), although the biological significance of this numerically modest difference is uncertain. In CD1 mice, the three formulations containing H70 (H70, H70+L460D, and H70+YLN) elicited similarly strong IgG responses (GM ELISA titers, >10,000) compared with the response in the alum placebo group (GM titer, <200) (Fig. 3D). However, in BALB/c mice, anti-H70 responses to H70+YLN were lower than those elicited by the formulations containing either CD2 or pUAB055. Nevertheless, even for H70+YLN, the GM titer was >10,000, compared with <200 for the alum placebo.

**Protective efficacy in sepsis models.** The efficacy of the vaccine formulations was determined using two sepsis models: i.p. challenge with one of three strains, D39 (serotype 2), P9 (serotype 6A), or 1861 (serotype 1), or i.v. challenge with strain DBL6A or A66.1 (serotypes 6B and 3, respectively). Immunized mice were challenged 2 weeks after the final immunization, and animals were monitored for survival for up to 21 days. In the i.p. challenge model, the H70+YLN, CD2+YLN, H70+L460D, YLN, and L460D vaccine groups all exhibited significant protection against two challenge strains, D39 and 1861 (Fig. 4A and B). However, only the trivalent H70+YLN group exhibited significant protection against strain P9, a clinical isolate that causes meningitis in approximately 50% of unprotected mice (Fig. 4C). In this experiment, any mice infected with P9 that displayed clinical signs of meningitis were promptly euthanized. The difference in protection seen between the trivalent H70+YLN and all the other groups, including the placebo control, was largely attributable to a lower rate of progression to meningitis, with only approximately 20% of mice immunized with H70+YLN showing symptoms, compared to approximately 50% for all other groups (results not shown). Peptides H70 and CD2 were not protective when given alone, but when each was combined with YLN, the level of protection increased significantly relative to that with YLN alone, indicating that the strongest protection is achieved by the combi-
FIG 4 Survival time of vaccinated mice in three sepsis models. (A to C) Intraperitoneal sepsis model. Mice were challenged with strain D39 (A), 1861 (B), or P9 (C). The solid lines denote the median survival time for each group, and mice that survived to 21 days postinfection were plotted as alive. Significant protection compared to that with the alum control group is indicated in each panel by asterisks (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). (D and E) Intravenous sepsis model. Mice were challenged with strain DBL6A (D) or A66.1 (E). The solid lines denote the median survival time for each group, and mice that survived to 21 days postinfection were plotted as alive. (F) Intratracheal sepsis/meningitis model. Mice were challenged with strain TIGR4X. The solid lines denote the median survival time for each group. The number of mice in each group and the number of mice alive at day 14 are depicted at the top of the panel.
nation of pneumolysoid and immunogenic portions of PspA and CbpA.

Mice immunized with either H70 or CD2 exhibited significant protection against challenge with DBL6A in the i.v. sepsis model compared to that in the alum control group (Fig. 4D). H70 immunization elicited slightly superior protection to that with CD2, but this was not statistically significant. When protection following immunization with either L460D or H70 was compared with that for the H70+L460D group, significant protection relative to that in the alum placebo was seen for both H70 (P < 0.0001) and H70+L460D (P < 0.0001) but not for L460D alone (Fig. 4D). However, the combination of H70+YLN elicited the strongest protection against strain DBL6A (P < 0.0001) (Fig. 4D) and very strong protection against A66.1 (P < 0.0001) (Fig. 4E).

Multivalent protein vaccine candidates confer protection in a meningitis/sepsis infection model. When mice are infected i.t. with strain TIGR4X (serotype 4), disease rapidly progresses from infection of the upper and lower respiratory tract to sepsis and meningitis. The survival time was the longest in mice immunized with combinations of all three antigens, followed by L460D or YLN alone (P < 0.0001) (Fig. 4D). Other groups, such as CD2-L460D, YLN+H70, and YLN+pUAB055, elicited modestly higher protection than that in the alum group. The proportion of mice developing meningitis, indicated by the degree of CFU recovery in cerebrospinal fluid, was significantly lower in mice immunized with L460D alone than in the alum group (P < 0.05). Further significant reductions were seen in groups immunized with L460D-NEEK and YLN (P < 0.05 in both cases), and similar low levels of meningitis were observed in any of the other groups immunized with antigen combinations including YLN (Fig. 5A). The numbers of bacteria in the nasopharynx of survivors at day 14 indicated that only animals immunized with YLN or pUAB055+YLN showed a significant decrease in bacterial load (Fig. 5B).

Single-valent and multivalent protein vaccine candidates confer protection against pneumonia. In a focal pneumonia model (without subsequent progression to sepsis), mice were challenged i.t. with type 19F strain EF3030. After 5 days, mice were euthanized, and blood and lungs were harvested for analysis of CFU recovery. No CFU were recovered from blood of any group. Analysis of CFU recovery from the lungs revealed that immunization with L460D alone (P = 0.0031) or in combination in either the trivalent YLN (P = 0.0007) or the divalent CD2-L460D (P = 0.023) constructs afforded significant protection compared to that in the alum control group (Fig. 5C).

**DISCUSSION**

This, to our knowledge, is one of the most comprehensive studies conducted to identify the best potential protein-based alternative
to the current polysaccharide-based pneumococcal vaccines. Here, we describe the testing of new vaccine formulations comprising multiple protein antigens in different challenge models. The protein antigens L460D, PspA, and CbpA used in this study are the best characterized pneumococcal proteins to date in terms of their roles in pathogenicity and protective efficacy. Furthermore, several derivatives of PspA have recently been shown to potentially confer protection with fewer safety concerns (42). It is therefore reasonable to test them in various combinations in order to identify the best combination of these protein antigens. The protein antigens L460D, pUA8057, H70, CD2, and YLN were tested singly or in various combinations in models of sepsis, pneumonia, and meningitis using three different mouse backgrounds and six different challenge strains. All combinations were highly immunogenic, with no indication of interference. Fusion constructs elicited titers to individual component antigens that were equal or higher than those of single proteins. Antihemolytic titers against wild-type pneumolysin were equivalent, regardless of construct. Intrapneural and subcutaneous routes of immunization were also equivalent.

Pneumolysin has long been recognized as a critical virulence factor in pneumococci, capable of lysing cells by forming membrane pores and interacting with the immune system by activating complement and inducing inflammation (17, 61–63). More recently, pneumolysin has been shown to be involved in evading recognition by pattern recognition receptors in the innate immune system (64, 65). Thus, a pneumolysin toxoid, such as L460D, is a highly desirable vaccine component. To limit the number of separate proteins in the multicomponent product, L460D was used as a backbone for several fusion proteins. The addition of CbpA and PspA derivatives (YPT-L460D-NEEK [YN] and CD2-L460D) expanded the anti-Ply-mediated protection to the pathogenic processes of adherence, penetration of the blood-brain barrier, and opsonization. In the case of pneumonia, PspA and L460D derivatives were important for protection, while CbpA components played a strong protective role against meningitis. The trivalent combinations CD2+YNL or H70+YNL elicited protection against all six serotypes tested in the challenge models.

A previous study characterized YLN in the i.t. meningitis model and found that immunization with this fusion protected against sepsis, meningitis, pneumonia, and otitis media (54). Passive protection was also examined; mice immunized with anti-YNL rabbit serum were also protected against these diseases. YLN was further shown to provide cross-protection against meningococcal and Haemophilus infection, as the sequence EPRNEEK in the NEEK peptide is able to bind to the same domain of the laminin receptor of the blood-brain barrier as Haemophilus influenzae and Neisseria meningitidis (52).

The PspA peptide CD2 has been examined in the i.v. sepsis model in a prior study (42). As mentioned above, CD2 contains the highly conserved proline-rich region of PspA present in all PspAs and almost all CbpAs. CD2 is advantageous over the N-terminal region of PspA for inclusion in a vaccine, as the CD2 region varies only slightly between PspA and CbpA and elicits cross-reactive antibodies to both PspA and CbpA. Immunization with CD2 or passive immunization with CD2 monoclonal antibodies elicited protection of mice against three challenge strains. Also, upon exposure of children to pneumococci, cross-reactive CD2 antibodies were detected, regardless of the PspA family of the infecting strains (43). In this study, we have shown that in a comparison of H70 and CD2, H70 appeared to more consistently elicit stronger protection than CD2, either singly or in combination with YLN, CD2 and H70 both contain the proline-rich region of PspA, while H70 has the additional SM1 peptide. This SM1 peptide is located just upstream of the proline-rich region of PspA in strain Rx1. Human lactoferrin is known to kill many species of bacteria, including pneumococci, and PspA has been observed to specifically inhibit in vitro killing of pneumococci by lactoferrinin (the iron-free form of lactoferrinin); this action is believed to be due to the SM1 peptide that blocks the binding of lactoferrinin to PspA (66). Thus, the addition of the SM1 peptide in H70 is likely to have provided enhanced protection over CD2.

Taken together, these results clearly indicate that the trivalent H70+YNL combination is the optimal protein vaccine candidate tested here. It consistently demonstrated significantly broad and strong protection against multiple diseases, such as sepsis, pneumonia, and meningitis, caused by different strains/serotypes in different animal models. We also show that the ability of the L460D antibody to neutralize the cytolytic activity of the wild-type toxin Ply was not compromised by creating fusion constructs that minimize vaccine components.

ACKNOWLEDGMENTS

This work was supported by grants from PATH (to J.C.P., E.I.T., and D.E.B.). E.I.T. was also supported by NIAID R0127913, the Schafer Charitable Gift, and the American Lebanese Syrian Associated Charities. J.C.P. is a National Health and Medical Research Council of Australia (NHMRC) Senior Principal Research Fellow. D.E.B. and S.K.H. were also supported by NIH grant R01-AI021458. R.K.T. is supported by grant R101 AI037657 from the NIH National Institute of Allergy and Infectious Diseases.

REFERENCES

1. O’Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T, Hib and Pneumococcal Global Burden of Disease Study Team. 2009. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374:893–902. http://dx.doi.org/10.1016/S0140-6736(09)61204-6.

2. World Health Organization. 2008. 23-valent pneumococcal polysaccharide vaccine, WHO position paper. Wkly Epidemiol Rec 83:373–384.

3. Weinberger DM, Trzcinski K, Lu YJ, Bogart D, Brandes A, Galagan J, Anderson PW, Malley R, Lipsitch M. 2009. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog 5:e1000476. http://dx.doi.org/10.1371/journal.ppat.1000476.

4. Feldman C, Anderson R. 2014. Review: current and new generation pneumococcal vaccines. J Infect Dis 199:309–325. http://dx.doi.org/10.1093/infdis/jit006.

5. Miller E, Andrews NJ, Waight PA, Slack MP, George RC. 2011. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 11:760–768. http://dx.doi.org/10.1016/S1473-3099(11)70090-1.

6. Pai R, Moore MR, Pääliviita T, Gertz RE, Whitney CG, Beall B, Active Bacterial Core Surveillance Team. 2005. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 192:1988–1995. http://dx.doi.org/10.1086/1488043.

7. Singleton RJ, Hennessy TW, Bulkrw LA, Hammt LL, Zhu T, Hurlburt DA, Butler JC, Rudolph K, Parkinson A. 2007. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297:1784–1792. http://dx.doi.org/10.1001/jama.297.16.

8. Weinberger DM, Malley R, Lipsitch M. 2011. Serotype replacement in disease after pneumococcal vaccination. Lancet 378:1962–1973. http://dx.doi.org/10.1016/S0140-6736(10)62225-8.
9. Domingues CM, Verani JR, Montenegro Renoiher EI, de Cunto Brande- 
dileone M, Flannya B, de Oliveira LH, Santos JB, de Moraes JC, Brásilian Pneumococcal Conjugate Vaccine Effectiveness Study Group. 2014. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Lancet Respir Med 2:646–471. http://dx.doi.org/10.1016/S2213-
2604/07/0086-8.
10. Moore CE, Paul J, Foster D, Mahra SA, Griffiths D, Knox K, Pete TE, Walker AS, Crook DW, Oxford Invasive Pneumococcal Surveillance Group. 2014. Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England. J Infect Dis 210:1001–1011. http://dx.doi.org/10.1093/infid-
j/210.10.1001.
11. Carter R, Wolf J, van Opinien T, Muller M, Obert C, Burnham C, 
Mann B, Li Y, Hayden RT, Pestina T, Persons D, Camilli A, Flynn PM, 
Tuomanen EI, Rosw JCH. 2014. Genomic analyses of pneumococci from 
children with sickle cell disease expose host-specific bacterial adaptations 
and deficits in current interventions. Cell Host Microbe 15:587–599. http: 
//dx.doi.org/10.1016/j.chom.2014.04.005.
12. McCool TL, Cabe TS, Tuomanen EL, Adrian P, Mitchell TJ, Weiser JN. 
2003. Serum immunoglobulin G response to candidate vaccine antigens 
during experimental human pneumococcal colonization. Infect Immun 
71:5724–5732. http://dx.doi.org/10.1128/IJ.71.10.5724-5732.2003.
13. Rapola S, Jännti V, Hakala R, Syrjanen R, Carlone GM, Sampson JS, 
Bries DE, Paton JC, Takala AK, Kilpi TM, Kähy vt H. 2000. Natural 
development of antibodies to pneumococcal surface protein A, pneumo-
coccal phase-adhesive A, and pneumolysin in relation to pneumococcal carriage and acute otitis media. J Infect Dis 182:1146–1152. http:
//dx.doi.org/10.1086/315822.
14. Simell B, Korkeila M, Pursiainen H, Kilpi TM, Kähy vt H. 2001. Pneu-
coccal carriage and otitis media induce salivary antibodies to pneumococcal 
surface adhesin A, pneumolysin, and pneumococcal surface protein 
A in children. J Infect Dis 183:887–896. http://dx.doi.org/10.1086 
319246.
15. Zhang Q, Choo S, Finn A. 2002. Immune responses to novel pneumo-
coccal polysaccharidem, PsPA, PsA, and CbpA in adenoidal B cells from 
children. Infect Immun 70:5363–5369. http://dx.doi.org/10.1128/
I.70.10.5363-5369.2002.
16. Bries DE, Paton JC, Swiatlo E, Hollingshead SK, Cate TR, Tuomanen EI, 
Mann B, Li Y, Hayden RT, Pestina T, Persons D, Camilli A, Flynn PM, 
Tuomanen EI, Rosw JCH. 1996. The contribution of pneumolysin to the pathogenicity of Streptococcus pneumoniae. Trends Microbiol 4:103–106. http://dx.doi.org/10.1016/0928-4449(96)85026-5.
17. Paton JC. 1998. Novel pneumococcal surface proteins: role in virulence 
and vaccine potential. Trends Microbiol 6:5–9. http://dx.doi.org/10. 
1016/S0928-4449(98)01220-7.
18. Paton JC. 2004. New pneumococcal vaccines: basic science developments, 
properties of pneumococcal surface protein A (PspA). J Exp Med 201:381–394. http://dx.doi.org/10.1084/jem.165.2.381.
19. Tuomanen EI, Pfister M, Martel J, Cate TR, Tuomanen EI, Adrian P, 
Mitchell TJ, Wang J, Weiser JN. 2002. Immune responses to novel pneumo-
coccal surface protein A (PspA) and proteins with similar properties. J 
Exp Med 201:381–394. http://dx.doi.org/10.1084/jem.165.2.381.
20. Genschmer KR, Accavitti-Loper MA, Bries DE. 2013. A modified sur-
face killing assay (MSKA) as a functional in vitro assay for identifying 
protective antibodies against pneumococcal surface protein A (PspA). 
Vaccine 32:39–47. http://dx.doi.org/10.1016/j.vaccine.2013.10.080.
21. Bries DE, King JD, Gray MA, McDaniel LS, Swiatlo E, Benton KA. 
1996. PsPA, a protection-eliciting pneumococcal protein: immunogenic-
ity and protective activity of isolated native PsPA in mice. Vaccine 14:858–867. http://dx.doi.org/10.1016/S0264-410X(96)82948-3.
22. McDaniel LS, Walsh VA, McDaniel DO, Bries DE. 1994. Localization of 
protection-eliciting epitopes on PsPA of Streptococcus pneumoniae 
within amino acid residues 192 and 260. Microb Pathog 17:323–337. http: 
//dx.doi.org/10.1016/S0882-4010(93)00138-7.
23. McDaniel LS, Sheffield JS, Delucchi P, Bries DE. 1991. PsPA, a surface 
protein of Streptococcus pneumoniae, is capable of eliciting protection 
against pneumococci of more than one capsular type. Infect Immun 59 :
222–228.
24. Brooks-Walter A, Bries DE, Hollingshead SK. 1999. The pspC gene of 
Streptococcus pneumoniae encodes a polymorphic protein, PspC, which 
elicits cross-reactive antibodies to PsPA and provides immunity to pneumo-
coccal bacteremia. Infect Immun 67:6333–6342.
25. Hollingshead SK, Becker R, Bries DE. 2000. Diversity of PsPA: mosaic 
genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68:5889–5900. http://dx.doi.org/10.1128/IAI.68.10.5889-
5900.2000.
26. Iannelli F, Ogguni MR, Pozzi G. 2002. Alleric variation in the highly 
morphophylic locus pspC of Streptococcus pneumoniae. Gene 284:63–71. 
http://dx.doi.org/10.1016/S0378-111X(01)00860-8.
27. McDaniel LS, Sheffield JS, Swiatlo E, Yother J, Crain MJ, Bries DE. 1992. 
Molecular localization of variable and conserved regions of pspA and identification of additional pspA homologous sequences in Streptococcus pneumoniae. Microb Pathog 13:261–269. http://dx.doi.org/10.1016/0882-4100(92)90036-N.
28. Daniels CC, Coan P, King J, Hall J, Benton KA, Bries DE, Hollings-
1088 cvi.asm.org Clinical and Vaccine Immunology October 2015 Volume 22 Number 10
head SK. 2010. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun 78:2163–2172. http://dx.doi.org/10.1128/IAI.01199-09.

43. Melin M, Coan P, Hollingshead S. 2012. Development of cross-reactive antibodies to the proline-rich region of pneumococcal surface protein A in children. Vaccine 30:7157–7160. http://dx.doi.org/10.1016/j.vaccine.2012.10.004.

44. Balachandran P, Brooks-Walter A, Virolainen-Julkunen A, Hollingshead SK, Briles DE. 2002. Role of pneumococcal surface protein C in nasopharyngeal carriage and pneumonia and its ability to elicit protection against carriage of Streptococcus pneumoniae. Infect Immun 70:2526–2534. http://dx.doi.org/10.1128/IAI.70.5.2526-2534.2002.

45. Orihuela CJ, Gao G, Francis KP, Yu J, Tuomanen EI. 2004. Tissue-specific contributions of pneumococcal virulence factors to pathogenesis. J Infect Dis 190:1661–1669. http://dx.doi.org/10.1086/424596.

46. Zhang Y, Masi AW, Barniak V, Mountzouros K, Hostetter MK, Green BA. 2001. Recombinant PspA protein, a unique histidine motif-containing protein from Streptococcus pneumoniae, protects mice against intranasal pneumococcal challenge. Infect Immun 69:3827–3836. http://dx.doi.org/10.1128/IAI.69.6.3827-3836.2001.

47. Cheng Q, Finkel D, Hostetter MK. 2000. Novel purification scheme and functions for a C3-binding protein from Streptococcus pneumoniae. Biochemistry 39:5450–5457. http://dx.doi.org/10.1021/bi002157d.

48. Dave S, Brooks-Walter A, Pangburn MK, McDaniel LS. 2001. PspC, a pneumococcal surface protein, binds human factor H. Infect Immun 69:3435–3437. http://dx.doi.org/10.1128/IAI.69.5.3435-3437.2001.

49. Hammerschmidt S, Talay SR, Brandtzaeg P, Chhatwal GS. 1997. SpSA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol Microbiol 25:1113–1124. http://dx.doi.org/10.1046/j.1365-2958.1997.5391899.x.

50. Janulczyk R, Iannelli F, Sjoholm D, Gao G, Björck L, Meri S. 2000. Novel purification scheme and functions for a C3-binding protein from Streptococcus pneumoniae. Biochemistry 39:5450–5457. http://dx.doi.org/10.1021/bi002157d.

51. Jarva H, Janulczyk R, Hellward J, Zipfel PF, Björck L, Meri S. 2002. SpPA, a novel pneumococcal surface protein with specific binding to secretory immunoglobulin A and secretory component. Mol Microbiol 25:1113–1124. http://dx.doi.org/10.1046/j.1365-2958.1997.5391899.x.

52. Orihuela CJ, Madhavi J, Thornton J, Mann B, Woolridge KG, Abouseada N, Oldfield NJ, Self T, Ala’Aldeen DA, Tuomanen EI. 2009. Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J Clin Invest 119:1638–1646. http://dx.doi.org/10.1172/JCI36759.

53. Luo R, Mann M, Lewis WS, Rowe A, Heath R, Stewart ML, Hamburger AE, Sivakolundu S, Lacy ER, Bjorkman PJ, Tuomanen E, Kriwacki RW. 2005. Solution structure of choline binding protein A, the major adhesin of Streptococcus pneumoniae. EMBO J 24:34–43. http://dx.doi.org/10.1038/sj.embry.7600490.

54. Mann B, Thornton J, Heath R, Wade KR, Tweten RK, Gao G, El Kasmi K, Jordan JB, Mitrea DM, Kriwacki R, Maisonneuve J, Alderson M, Tuomanen EI. 2014. Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid-CbpA peptide recombinant fusion protein. J Infect Dis 209:1116–1125. http://dx.doi.org/10.1093/infdis/jit502.

55. Harvey RM, Ogguniyi AD, Chen AY, Paton JC. 2011. Pneumolysin with low hemolytic activity confers an early growth advantage to Streptococcus pneumoniae from macrophages. Infect Immun 79:4122–4130. http://dx.doi.org/10.1128/IAI.05418-11.

56. Harvey RM, Hughes CE, Paton AW, Trappetti C, Tweten RK, Paton JC. 2014. The impact of pneumolysin on the macrophage response to Streptococcus pneumoniae is strain-dependent. PLoS One 9:e103625. http://dx.doi.org/10.1371/journal.pone.0103625.

57. National Health and Medical Research Council. 2004. Australian code of practice for the care and use of animals for scientific purposes, 7th ed. Australian Government, National Health and Medical Research Council, Canberra, Australian Capital Territory, Australia. https://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/ea16_animal_code.pdf.

58. Parliament of South Australia. 1985. Animal Welfare Act 1985. Parliament of South Australia, Adelaide, South Australia, Australia.

59. Jalonen E, Paton JC, Koskela M, Kerttula Y, Leinonen M. 1989. Measurement of antibody responses to pneumolysin—a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia. J Infect 19:127–134. http://dx.doi.org/10.1016/S0163-4458(89)91864-1.

60. Paton JC, Lock RA, Hansman DJ. 1983. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun 40:548–552.

61. Braun JS, Novak R, Gao G, Murray PJ, Shenep JL. 1999. Pneumolysin, a protein toxin of Streptococcus pneumoniae, induces nitric oxide production by human macrophages. Infect Immun 67:3750–3756.

62. Cockeren R, Theron AJ, Steel HC, Matlola NM, Mitchell TJ, Feldman C, Anderson R. 2001. Proinflammatory interactions of pneumolysin with human neutrophils. J Infect Dis 183:560–611. http://dx.doi.org/10.1086/318536.

63. Kadioglu A, Gingles NA, Grattan K, Kerr A, Mitchell TJ, Andrew PW. 2000. Host cellular immune response to pneumococcal lung infection in mice. Infect Immun 68:492–501. http://dx.doi.org/10.1128/IAI.68.2.492-501.2000.

64. Marriott HM, Mitchell TJ, Dockrell DH. 2008. Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med 8:497–509. http://dx.doi.org/10.2174/15665240878574924.

65. Wittenrath M, Pache F, Lorenz D, Koppe U, Gubier B, Tabeling C, Reppe K, Meixenberger K, Dorhui A, Ma J, Holmes A, Tendelenburg G, Heimesaat MM, Bereswill S, van der Linden M, Tschopp J, Mitchell TJ, Suttorp N, Opitz B. 2011. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J Immunol 187:434–440. http://dx.doi.org/10.4049/jimmunol.1003143.

66. Mizra S, Wilson L, Benjamin WH, Jr, Novak J, Barnes S, Hollingshead SK, Briles DE. 2011. Serine protease PrtA from Streptococcus pneumoniae plays a role in the killing of S. pneumoniae by apolactoferrin. Infect Immun 79:2440–2450. http://dx.doi.org/10.1128/IAI.00489-10.